Pluristem Therapeutics (NASDAQ: PSTI): Current price $3.09
Pluristem has reported that subsequent to favorable preclinical studies, United Therapeutics Corporation received the green light to perform a human Phase I evaluation in Australia using Pluristem’s PLacental eXpanded cells in patients diagnosed with Pulmonary Arterial Hypertension. On June 20, 2011 United Therapeutics and Pluristem entered into a licensing agreement through which United Therapeutics will develop, market and sell Pluristem’s PLX-PAD cells for PAH.